44results about How to "Improve fibrosis" patented technology

The invention discloses a method for separating and culturing primary chicken hepatocytes. According to the method, EGTA (Ethylene Glycol Tetraacetic Acid) with low hepatotoxicity is added into a perfusate A to loosen the junction between hepatocytes, so that the dispersion degree of the to-be-separated hepatocytes is increased; double resistance is added into the perfusate A, a perfusate B and D-Hanks flushing fluid, so that the pollution is further prevented; and circulating perfusion digestion is adopted during digestion perfusion, so that the perfusion cost is greatly reduced. A serum-free cultural method of the chicken hepatocytes is established; compared with a traditional serum cultural method, the method disclosed by the invention has the same effect on the aspects of cell quantity, activity, function and the like, so that the problems caused by the existence of serum are solved and a foundation is laid for the substance metabolism study and biological product preparation on the basis of the chicken hepatocyte culture.

The invention discloses a silicosis treatment aerosol containing a human mesenchymal stem cell exosome extract and a preparation method thereof, wherein the main component of the aerosol is the high-concentration mesenchymal stem cell exosome extract. The mesenchymal stem cells can secrete various cell factors in the culture process, and the cell factors can penetrate into the basal layer of an inner membrane, promote tissue differentiation of the inner membrane, angiogenesis and growth of granulation tissues, promote regeneration and repair of damaged skin tissue structures, reduce generation of scar connective tissues and reduce bacterial infection and inflammatory reaction of wound surface tissues. According to the aerosol and the preparation method thereof, a method of continuous starvation of the mesenchymal stem cells is adopted, a high-concentration human mesenchymal extract can be obtained in a short period of time, and a big amount of stem cell exosomes can be separated from the mesenchymal extract by an exosome extractor. The aerosol containing the high-concentration mesenchymal stem cell exosome extract disclosed by the invention is suitable for the restoration and treatment of silicosis.

The invention discloses a traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis. Active pharmaceutical ingredients of the traditional Chinese medicine composition comprise, by weight, 10-15 parts of the root of red-rooted salvia, 10-60 parts of astragalus membranaceus, 10-30 parts of herba epimedii, 5-30 parts of sinensis and 3-30 parts of prepared rhubarb. Clinical researches show that 168 patients with chronic renal insufficiency are treated by the traditional Chinese medicine composition, a remarkable clinical effect is obtained, clinical symptoms are reduced, the clinical symptoms of some patients are basically eliminated, the renal functions of the patients can be remarkably improved, blood urea nitrogen (BUN) and creatinine (Scr) are obviously reduced, and total effective rate achieves 88.66%. Animal researches show that the traditional Chinese medicine composition can delay development of chronic renal failure, and the mechanism of the traditional Chinese medicine composition is relative to effects of effectively restraining precipitation of renal tissue collagen and secretion of TGF (transforming growth factor)-beta, accordingly restraining renal fibrosis, and the like. The traditional Chinese medicine composition is low in clinical application cost and excellent in curative effect, and is safe and reliable.

The invention discloses a method for producing soybean tissue protein by using the high-temperature soy bean dregs as the raw material, belonging to the filed of the food processing biotechnology. According to the technical scheme, the method comprises the following steps: dissolving compound protease in water to prepare protease solution, wherein the addition amount of the compound protease is 0.1-0.5 percent of that of the high-temperature soy bean dregs; stirring evenly the high-temperature soy bean dregs and the protease solution in a stirrer, wherein the proportion of the high-temperature soy bean dregs to the protease solution is 1:0.5; and activating the protein in the high-temperature soy bean dregs by decomposing with the protease solution at 30-50 DEG C for 12-20h; extruding the activated high-temperature soy bean dregs into the soybean tissue protein in a soybean tissue protein forming machine; and drying and packaging the soybean tissue protein to obtain the soybean tissue protein product. The high-temperature soy bean dregs are activated by being decomposed with the protease, thus the nitrogen solubility index is increased, and the organization effect and the fibrosis effect of the protein can be improved. The soybean tissue protein product is in the structure of fiber, is chewable and has no bitter flavor and beany flavor. The method has the characteristic of mild reaction condition, is beneficial to improving the ecology and environment and producing the natural products and meets the demands of green chemistry.

The invention provides feed for improving the meat quality of yellow-head catfish and a preparation method thereof. The feed is characterized by being prepared from the following ingredients in percentage by mass: 0.08 to 0.1 percent of choline chloride, 0.2 to 0.5 percent of lutein, 0.05 to 0.1 percent of astaxanthin, 2 to 3 percent of pine needle powder, 2 to 3 percent of monocalcium phosphate, 10 to 15 percent of bean pulp, 5 to 10 percent of peanut meal, 10 to 15 percent of chellocken meal, 15 to 20 percent of imported fish meal, 3 to 4 percent of fish oil, 25 to 30 percent of flour, 15 to 20 percent of miscellaneous meal, 0.1 to 0.3 percent of trace elements and 0.1 to 0.15 percent of vitamins. The trace elements are formed by mixing iron methionine, zinc methionine and manganese methionine; the vitamins are formed by mixing vitamin A, vitamin D, vitamin E, vitamin K, vitamin C and vitamin B.

The invention relates to a schisandra chinensis-oyster dealcoholic liver-protecting health medicine and a preparation method thereof. According to the invention, schisandra chinensis and oyster are adopted in compatibility and prepared into a health medicine with dealcoholic and liver-protecting main effects, and oyster extract taken as a major medicine, schisandra chinensis extract, microcrystal cellulose, a filling agent, CMS-Na, an internal disintegrating agent, a water wetter and talcum powder are prepared into the schisandra chinensis-oyster dealcoholic liver-protecting health medicine. Excessive drinking can do a certain harm to health, so that definite effects of the schisandra chinensis-oyster dealcoholic liver-protecting health medicine on multiple complications, such as hepatic damage, cardia-cerebrovascular diseases, stomachache, obesity and hyperlipemia, of alcoholism need to be contained; and the schisandra chinensis-oyster dealcoholic liver-protecting health medicine adopts schisandra chinensis and oyster and also pays attention to concomitant symptoms of drinking, so that the aim of relieving both primary and secondary symptoms is achieved.

The invention discloses a Mongolia astragalus pathogenesis-related protein, a crystal thereof, a growth method and an application. The Mongolia astragalus pathogenesis-related protein has any amino acid sequence of (a) to (c), (a) is an amino acid sequence as shown in SEQ ID NO. 1, (b) is an amino acid sequence with at least 90% of homology of the amino acid sequence as shown in SEQ ID NO. 1, or is a homologous compound, derivative and fragment or mutant without losing biological activity of the amino acid sequence as shown in (a) or (b). According to the Mongolia astragalus pathogenesis-related protein, the amino acid sequence of AmPR-10 is firstly disclosed, identification and functional study of the AmPR-10 are facilitated, the application of the AmPR-10 in preparation of a medicine fortreating idiopathic pulmonary fibrosis is further discovered, treatment effects of the AmPR-10 are obvious, the AmPR-10 serves as an extract of natural Chinese herbal medicines, so that the AmPR-10 is wide in source, low in toxicity and suitable for clinical application.

The invention relates to new application and a new action mechanism of verbascoside, in particular to application of verbascoside in the drugs for treating and preventing type II diabetic nephropathy,and the research on the protection function of the verbascoside for the type II diabetic nephropathy and the action mechanism thereof. Results show that the verbascoside can alleviate liver injury caused by high glucose and lower the serum creatinine, urea nitrogen and urinary microalbuminuria levels, the blood fat level (total cholesterol and triglyceride) and the fasting blood-glucose and bloodinsulin level of spontaneous diabetes db / db mice; TGF (Transforming Growth Factor)-beta 1 and the signal transduction protein Smad3 and Smad4 and alpha-SMA protein expression thereof in a kidney tissue are obviously lowered; meanwhile, the verbascoside can alleviate the liver injury caused by high glucose; HK-2 proliferation and EMT (pithelial-Mesenchymal Transition) formation can be inhibited. In conclusion, the verbascoside has an obvious protection function on the type II diabetic nephropathy, the action mechanism of the verbascoside is that the kidney protection function of the verbascoside is implemented through oxidative stress reaction regulation and control, TGF-beta / smad signaling channel inhibition and kidney fibrosis alleviation.

The invention relates to a new purpose of embelia parviflora wall, namely a new purpose of the embelia parviflora wall for preparing medicines for treating liver fibrosis, in particular to a new purpose of an embelia parviflora wall extract and general flavone of the embelia parviflora wall for preparing the medicines for treating the liver fibrosis.

Non-activated tissue-regeneration polypeptides (TRPs) and their preparation methods are disclosed. The TRPs include: a protein transduction domain (PTD) making the polypeptides to permeate a cell membrane without cell membrane receptors; a furin activation domain (FAD) which has at least one proprotein convertase cleavage site and which can be cleaved by the proprotein convertase and activate a tissue regeneration domain (TRD) in cells; and a tissue regeneration domain (TRD) which can be activated by the proprotein convertase cleavage of the FAD to stimulate the growth or formation of tissues or to induce the regeneration of tissues. The TRPs can be mass-produced by cultured bacteria, such as recombinant E. coli, are in a non-activated state before in vivo administration, and their separation, purification, handling, storage and administration are simple and convenient. The in vivo administration of the TRPs is useful to stimulate the formation or regeneration of tissues, such as bones or cartilages, or to improve the fibrosis and cirrhosis of organs, such as kidneys, liver, lungs and heart by pharmacological mechanisms completely different from those of prior rhBMPs or TGF-β proteins.

Non-activated tissue-regeneration polypeptides (TRPs) and the preparation methods thereof are disclosed. The TRPs contain: a protein transduction domain (PTD) making the polypeptides to permeate a cell membrane without cell membrane receptors; a furin activation domain (FAD) which has at least one proprotein convertase cleavage site and which can be cleaved by the proprotein convertase and activate a tissue regeneration domain (TRD) in cells; and a tissue regeneration domain (TRD) which can be activated by the proprotein convertase cleavage of the FAD to stimulate the growth or formation of tissues or to induce the regeneration of tissues. The TRPs can be practically mass-produced by the culture of bacteria, such as recombinant E. coli, and are in a non-activated state before in vivo administration. Thus, their production cost is only a few tenths of the prior active proteins having uses similar thereto, and processes for their separation, purification, handling, storage and administration are significantly simple and convenient. The in vivo administration of the TRPs can stimulate the formation or regeneration of tissues, such as bones or cartilages, or improve the fibrosis and cirrhosis of organs, such as kidneys, liver, lungs and heart by pharmacological mechanisims completely different from those of prior rhBMPs or TGF-β proteins. Accordingly, the TRPs will be useful as drugs having new mechanisms.

The invention provides an application of magnesium lithospermate B or a pharmaceutical composition containing the lithospermate B in preparation of a medicine. The medicine is used for treating and / orpreventing liver injury, especially liver injury caused by hepatic ischemia reperfusion. According to the invention, a mouse hepatic ischemia reperfusion animal model is utilized to systematically prove the treatment and protection effects of the magnesium lithospermate B or the pharmaceutical composition containing the magnesium lithospermate B, such as salvianolate, on hepatic ischemia reperfusion for the first time, the internal mechanism of the medicine is clarified, and a theoretical basis is provided for clinical application.

The invention specifically relates to application of the enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to preparation of drugs or / and health products used for preventing or / and treating hepatic fibrosis, belonging to the technical field of prevention and treatment of hepatic fibrosis. The invention discloses novel pharmaceutical application of the enzymatic hydrolysates of total glycosides of grosvenor momordica fruit, i.e., application to the drugs or / and health products used for preventing or / and treating hepatic fibrosis. Experimental materials used in the invention are derived from original plants which are widely available; and the enzymatic hydrolysates are low in cost, definite in extract activity and have good practical value.

The invention specifically relates to application of mogrol to preparation of drugs or / and health products used for preventing or / and treating hepatic fibrosis, belonging to the field of crude drugs. Experimental results prove that mogrol can substantially inhibit deposition of hepatocyte collagen, suppress hyperplasia of hepatic fibroblasts, reduce secretion of alpha-SMA in hepatic tissue and substantially improve hepatic fibrosis. Mogrol is definite in structure, good in stability, easily controllable in quality and cost, derived from the extract of natural plants, clear in activity, low in toxicity and side effect, provides a novel option and means for treatment or / and prevention of hepatic fibrosis, and has good practical value.

The invention provides a traditional Chinese medicine composition for organ fibrosis. The traditional Chinese medicine composition is characterized by being prepared from the following components according to a weight ratio: 40 to 85 parts of dragon's blood, 40 to 85 parts of radix notoginseng, 80 to 125 parts of bulbus fritillariae thunbergii, and 140 to 210 parts of semen coicis. Proofed by experiment, the traditional Chinese medicine composition has the advantages that the fibrosis of liver, lung, uterus and kidney organs can be effectively treated by low, medium and high doses, and the dose reliance is realized; and the administration type is diversified, the defects of the existing medicine are overcome, and the application prospect is broad.

The invention aims at providing lonicera japonica, lonicera japonica extract and a novel use of a traditional Chinese medicine composition comprising the lonicera japonica. The research proves that the lonicera japonica has the effect for inhibiting the excessive thickness of a wall, delaying the cardiac remodeling, improving the heart function and improving the myocardial fibrosis.

The invention relates to an application of Chinese pulsatilla root in the preparation of drugs for treating heart failure; and the research finds that Chinese pulsatilla root can inhibit excess thickness increasing of ventricular walls, delay cardiac remodeling, improve the functions of heart, obviously reduce the expression of ANP and BNP, and relieve myocardial fibrosis.

The invention discloses a medicine for treating hepatitis B. The medicine consists of the following medicinal materials in parts by weight: 15-20g of rhizoma polygoni cuspidate, 10-15g of herba artemisiae scopariae, 6-10g of radix sophorae flavescentis, 10-15g of herba taraxaci, 10-15g of herba patriniae, 15-25g of poria, 10-15g of rhizoma alismatis, 12-10g of cortex moutan, 15-25g of radix paeoniae rubra, 15-25g of radix salviae miltiorrhizae, 10-15g of radix curcumae, 8-12g of hizoma curcumae, 15-25g of radix cyathulae, 10-15g of herba ecliptae, 10-15g of glossy privet fruits, 10-15g of fructus hippophae, 15-30g of radix astragali, 15-25g of fruits of Chinese wolfberry, 15-20g of herba sedi, 15-30g of radix angelicae sinensis, 20-30g of radix paeoniae alba, 6-10g of cyrtomium rhizome, 6-10g of folium isatidis, 10-15g of radix isatidis, 6-12g of polyporus umbellatus, 10-15g of spreading hedyotis herb, 20-30g of herba taxilli, 20-30g of white atractylodes rhizome, 6-10g of liquorice root, 10-15g of fructus forsythiae and 20-30g of honeysuckle flowers. The medicine provided by the invention is capable of recovering normal liver functions through oral administration of traditional Chinese medicines, and the medicines is capable of eliminating hepatitis B viruses and solving pain in patients; the medicine is capable of tonifying liver and kidney, and the medicine has the advantages of being short in treatment time, high in cure rate, free from toxic and side effects, rapid to take effects, free from recurrence after recovery and the like.

The invention discloses application of a FGFR2b inhibiting molecule in preparation of a drug for treating a PAF-mediated disease. The application is a research result obtained on the basis of that aninventor of the invention discovers that FGF-7 can induce generation of a platelet activating factor PAF. The inventor of the invention discovers that the rising of a level of a proinflammatory factorcan be induced after the PAF is generated, then, an inflammatory reaction is initiated, a molecule inhibiting bonding between the FGF-7 and FGFR2serves as a competitive antagonist of FGF7 and is bonded to a specific receptor FGFR2b of the FGF7 so as to prevent the FGFR2b from being activated into phosphorylated FGFR2b, and an excessive inflammatory reaction can be effectively inhibited, so that ARDS symptoms are treated, and lung fibrosis can be improved.

The invention belongs to the field of preparations and provides a preparation containing a camellia oleifera extract and application of the preparation. Camellia oleifera oil is adopted as the camellia oleifera extract. The provided preparation containing the camellia oleifera extract can effectively alleviate liver fibrosis conditions and bring a new approach for the treatment of liver fibrosis.

The invention provides the application of the drug glycoside in the preparation of medicines for treating, preventing, alleviating and / or alleviating diseases related to heart failure. The research of the present invention shows that Dangdaoside can inhibit the excessive thickening of the ventricular wall, delay myocardial remodeling, improve myocardial fibrosis and improve cardiac function; in addition, Dangdaoside can promote the recovery of the systolic / diastolic function of damaged cardiomyocytes, And it has a protective effect on cardiac ischemia-reperfusion injury.

The invention discloses an application of Abemaciclib in preparation of a medicine for treating NAFLD. After the Abemaciclib is administered to a C57BL / 6 mouse by intragastric administration for 2 weeks, histopathology and serum biochemical results show that the Abemaciclib can improve the liver lipidemia of the mouse and reduce the contents of serum ALT, AST and liver triglyceride. In-vitro experiment results show that the Abemaciclib can resist oxidative stress damage of cells through SESN2 and other mediated anti-oxidative stress pathways. In addition, our studies found that Abemaciclib caninduce HepG2 cells to form intracytoplasmic vacuoles similar to autophagy, presuming that Abemaciclib may improve NASH by inducing autophagy and inhibiting liver fibrosis.

The invention discloses a method for separating and culturing primary chicken hepatocytes. According to the method, EGTA (Ethylene Glycol Tetraacetic Acid) with low hepatotoxicity is added into a perfusate A to loosen the junction between hepatocytes, so that the dispersion degree of the to-be-separated hepatocytes is increased; double resistance is added into the perfusate A, a perfusate B and D-Hanks flushing fluid, so that the pollution is further prevented; and circulating perfusion digestion is adopted during digestion perfusion, so that the perfusion cost is greatly reduced. A serum-free cultural method of the chicken hepatocytes is established; compared with a traditional serum cultural method, the method disclosed by the invention has the same effect on the aspects of cell quantity, activity, function and the like, so that the problems caused by the existence of serum are solved and a foundation is laid for the substance metabolism study and biological product preparation on the basis of the chicken hepatocyte culture.

The present invention provides a use of the DLL4 cell factor in preparing a drug for treating fulminant hepatic failure. DLL4 can not only significantly improve the survival rate in a treatment of fulminant hepatic failure, but also significantly improve the survival rate by improving prognosis of a treatment of a severe or terminal stage hepatic disease having a similar underlying cause, disease progression and prognosis.

The invention discloses application of N-substituted phenyl-2-pyridone compounds or pharmaceutically acceptable salts thereof in treatment of pulmonary fibrosis, and belongs to the technical field of medicines. The invention provides an application of the compound in treatment of pulmonary fibrosis, and the compound can delay the progress of pulmonary fibrosis, has a good effect of preventing and treating pulmonary fibrosis, and also has good safety. Compared with a clinical first-line anti-pulmonary fibrosis drug pirfenidone, the drug provided by the invention has a better anti-pulmonary fibrosis curative effect, is expected to be developed into an efficient drug for treating pulmonary fibrosis, and provides a better drug choice for preventing and treating pulmonary fibrosis.

The invention discloses an application of chaetocin in preparation of a medicine used for preventing and treating heart diseases. Experimental research shows that chaetocin has effects of obviously reducing myocardial fibrosis degree and increasing a pressure load for inducing heart function, can prevent myocardial hypertrophy and ventricular remodelling and delay heart failure, and can inhibit myocardial cell oxidative stress caused by acute myocardial infarction, reduce ischemic infarction area, reduce myocardial cell oxidative stress, maintain normal function of myocardial cells and delay heart failure and displays a good heart disease preventing and treating effect, and no obvious adverse effect is produced in an experiment process, so that chaetocin is hopeful of being developed into a new generation safe and effective heart disease preventing and treating medicine.

The invention discloses a preparation method of a tumor cell vaccine targeting CAFs, and belongs to the technical field of biological medicines, the method is as follows: lentiviral packaging plasmids are adopted to infect tumor cells to obtain a stable expression strain, and then the stable expression strain is inactivated to obtain the tumor cell vaccine targeting CAFs; the invention also discloses application of the vaccine prepared by the method. On the basis of a brand-new preparation method, the prepared vaccine can more stably express an antigen, the immunotherapy response rate is higher, the effect is better and more stable, and the obtained vaccine is a broad-spectrum vaccine and can treat more than 90% of tumors from epithelium, part of soft tissue tumors and melanoma; besides, the vaccine can also enhance the radiosensitivity of tumors, can achieve a better effect when used in combination with radiotherapy, especially ablation radiotherapy, and can improve fibrosis caused by radiotherapy and reduce toxic and side effects of radiotherapy.

The invention relates to low-interfering RNA (ribonucleic acid) medicine for treating chronic hepatitis B and hepatic fibrosis. The RNA medicine comprises 19bp oligonucleotides; the shRNA expression is driven by H1 promoters; the medicine is packaged into recombinant viruses by using AAAV2; the transcription, the copying and the expression of HBV (hepatitis B virus) can be obviously inhibited on the HepG2.2.15 cells; the production of the HBV and the occurrence of hepatic fibrosis can be obviously inhibited; the HBV genome in the serum and the liver are obviously reduced; the HBVmRNA in the liver is lowered by more than 90 percent; the surface antigen in the serum is also lowered by more than 10 times; the collagen accumulation in the liver and the collagenous fiber generation can be obviously reduced; the form of the liver cells can be converted into light fibrosis from heavy fibrosis.